# Remix Therapeutics

Source: https://onco.cc/companies/remix-therapeutics/  
OnCo record `remix-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Remix Therapeutics is a Massachusetts biotech that makes small molecules to change how RNA is processed; REM-422 destroys the messenger RNA for the transcription factor MYB, a driver of adenoid cystic carcinoma and acute myeloid leukaemia.

## Summary

Remix Therapeutics uses its REMaster platform to design small molecules that reprogramme RNA splicing and stability. REM-422 induces a poison exon in MYB mRNA, marking it for degradation and lowering MYB protein; it is in phase 1 trials in adenoid cystic carcinoma and in acute myeloid leukaemia and higher-risk myelodysplastic syndromes. The company has partnerships with Janssen and Roche on other RNA-processing targets.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Remix Therapeutics, Inc.
- Tags: drug-maker
- HQ: Watertown, Massachusetts
- Type: biotech
- Website: https://www.remixtx.com/

## Sources

- Official website: https://www.remixtx.com/

## Connected records

- drugs: [REM-422](https://onco.cc/drugs/rem-422/)

---
JSON: https://onco.cc/api/v1/entities/remix-therapeutics.json